Avalo Therapeutics Appoints Paul Varki as Chief Legal Officer; Grants Inducement Stock Option

Avalo Therapeutics, Inc.

Paul Varki appointed Chief Legal Officer effective June 24, 2024; 20+ years pharma/biotech legal experience.
Compensation includes $465K base salary, up to 40% target bonus, $50K sign-on cash award (12-month clawback).
Inducement option to purchase 150,000 shares vesting over 4 years (1-year cliff); exercise price set at June 24 close.
Varki previously US General Counsel at Idorsia, SVP/GC at Braeburn/Egalet, and 12 years at GSK.
Severance: 9 months salary (12 on change in control), pro-rated bonus, accelerated option vesting, 12 months COBRA.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Paul Varki

Chief Legal Officer

AVTX · Avalo Therapeutics, Inc.

Effective: 2024-06-24
Filed: June 24, 2024, 7:59 PM ET

On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul Varki was appointed as Chief Legal Officer at Avalo Therapeutics, Inc..

Action: appointed
Role: Chief Legal Officer

Exact text from the filing

On June 24, 2024, Avalo Therapeutics, Inc. (the “Company”) announced the appointment of Paul Varki as Chief Legal Officer of the Company.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-029564

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.